Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Mateo, J; de Bono, JS; Fizazi, K; Saad, F; Shore, N; Sandhu, S; Chi, KN; Agarwal, N; Olmos, D; Thiery-Vuillemin, A; &#214;zg&#252;roğlu, M; Mehra, N; Matsubara, N; Young Joung, J; Padua, C; Korbenfeld, E; Kang, J; Marshall, H; Lai, Z; Barnicle, A; Poehlein, C; Lukashchuk, N; Hussain, M

Author(s): Mateo, J; de Bono, JS; Fizazi, K; Saad, F; Shore, N; Sandhu, S; Chi, KN; Agarwal, N; Olmos, D; Thiery-Vuillemin, A; Özgüroğlu, M; Mehra, N; Matsubara, N; Young Joung, J; Padua, C; Korbenfeld, E; Kang, J; Marshall, H; Lai, Z; Barnicle, A; Poehlein, C; Lukashchuk, N; Hussain, M;
Details: Publication Year 2024-02-10,Volume 42,Issue #5,Page 571-583
Journal Title: Journal of Clinical Oncology
Publication Type: Research article
Abstract: Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Publisher: American Society of Clinical Oncology
Keywords: Humans; Male; BRCA1 Protein/genetics; BRCA2 Protein/genetics; Kaplan-Meier Estimate; Phthalazines/therapeutic use; Piperazines/therapeutic use; *Prostatic Neoplasms, Castration-Resistant/drug therapy/genetics
Department(s): Medical Oncology
Publisher's Version: https://doi.org/10.1200/jco.23.00339
Open Access at Publisher's Site: https://doi.org/10.1200/jco.23.00339
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-03-13 05:27:09

Last Modified: 2024-03-13 05:27:28